Please Scroll Down to See Forums Below 
Well guys putting together a short Osta Guide.
So science related info
Activity of MK-2866:
MK-2866 is an androgen receptor modulator (SARM) with anabolic activity. Lack of PSA increases further corroborated selective anabolic effects of Ostarine (MK-2866). Ostarine (MK-2866) also resulted in a dose-dependent decrease in LDL and HDL cholesterol levels, with the average LDL/HDL ratio remaining in the low risk category.
SARMs create selective anabolic activity at certain androgen receptors and not others, hence their name. SARMs such as MK-2688 do not have androgenic activity in non-skeletal tissues.
Ostarine SARM:
-Lean mass gains (doses as low as 5mg to cause muscle growth)
-Accelerated fat loss (much moreso than S4 and at doses as low as 5mg ED)
-Joint soothing/healing effects
-Half life is 24 hours (one dose per day optimal)
-Can go up to 50mg ED with no known side effects ( IMO anything beyond 30 is a waste)
Ostarine (CAS# 1235370-13-4) is a research chemical developed by GTx Inc. It is undergoing Phase III (human) research trials in the USA. Ostarine belongs to a class of chemicals known as SARMs or selective androgen receptor modulators. SARMs create selective anabolic activity at certain androgen receptors and not others, hence their name. Compared to testosterone, the sex hormone, the advantage of SARMs such as Ostarine is that they do not have androgenic activity in non-skeletal-muscle tissues.
Testosterone and other androgenic anabolic steroids (AAS) are very effective at preventing muscle-wasting as well as increasing appetite and physical strength in humans and animal test subjects. However, AAS have a specific set of side-effects related to their non-specific androgen receptor activity that makes them contraindicated in many cases where they would otherwise be useful. Additionally, testosterone is subject to enzymatic conversion to a number of other bioactive hormones such as estrogen via the aromatase enzyme and DHT via the 5-alpha-reductase enzyme. While additional drugs may be prescribed to lower aromatase and 5-AR, or to minimize the side effects of AAS in some other fashion, testosterone is primarily only indicated for male hormone replacement therapy due to the fact that it is a problematic and complicated compound to use for its androgenic properties and the side-effects can vary greatly from individual to individual.
Ostarine exerts its anabolic effects on skeletal muscle tissue almost exclusively, and therefore represents a new potential treatment option for a wide spectrum of conditions from age-related muscular atrophy (sarcopenia), AIDS or cancer-related wasting/cachexia, and even an agent to minimize atrophy during recovery periods from serious surgery or similar situations. It is effective in not only maintaining lean body mass (LBM) but actually increases it.
Currently used androgens for male hormone replacement therapy are typically injectable or skin delivery formulations of testosterone or testosterone esters. Injectable forms of testosterone esters (such as testosterone enanthate, propionate, or cypionate) produce undesirable fluctuations in testosterone blood levels, with overly high levels shortly after injection and overly low afterward. Skin patches do provide a better blood level profile of testosterone, but skin irritation and daily application still limit their usefulness. Oral androgens are not currently used due to concerns about liver toxicity.
SARMs provide the opportunity to design molecules that can be delivered orally, but that selectively target the androgen receptors in different tissues differently. The goal of research in this area is to allow a customized response: Tissues that are the target of the therapy will respond as they would to testosterone; other tissues where undesirable side-effects are produced will not.
None of the SARMs yet developed are truly selective for anabolic effects in muscle or bone tissues without producing any androgenic effects in tissues such as the prostate gland, however several non-steroidal androgens show a ratio of anabolic to androgenic effects of greater than 3:1 and up to as much as 10:1, compared to testosterone, which has a ratio of 1:1.[2][3][4]
This suggests that, while SARMs are likely to show some virilizing effects when used at high doses (e.g., use by bodybuilders), at lower therapeutic doses they may well be effectively selective for anabolic effects, which will be important if SARMs are to have clinical application in the treatment of osteoporosis in women. One substantial advantage of even the first-generation SARMs developed to date is that they are all orally active without causing liver damage, whereas most anabolic steroids are not active orally and must be injected, and those anabolic steroids that are orally active tend to cause dose-dependent liver damage, which can become life-threatening with excessive use. Research is continuing into more potent and selective SARMs, as well as optimising characteristics such as oral bioavailability and increased half-life in vivo, and seeing as the first tissue-selective SARMs were only demonstrated in 2003, the compounds tested so far represent only the first generation of SARMs and future development may produce more selective agents compared to those available at present
-Making the best use of it-
if you look are big time body builders they all run long term cycles. It essential for big time growth, growth is slow and the only way to go about it is the slow n steady approach. With all the PH/oral AAS users here I think a bridge between a sarm/ph/sarm is the best approach.
I am partial to SS because of quality/purity reasons but other companies are ok too. I just want the best, and honest, i think they are more potent/anabolic also.
EX.
osta 1-4 @ 20mg
helladrol 4-10 @ 75mg
osta 10-16 @ 30mg (while in pct)
osta @ 15mg / S4 @ 50mg (pulse s4 to avoid vision sides) 1-6
beastdrol/diesel V2 6-10
osta @ 30mg 10-14 (while in pct)
So science related info
Activity of MK-2866:
MK-2866 is an androgen receptor modulator (SARM) with anabolic activity. Lack of PSA increases further corroborated selective anabolic effects of Ostarine (MK-2866). Ostarine (MK-2866) also resulted in a dose-dependent decrease in LDL and HDL cholesterol levels, with the average LDL/HDL ratio remaining in the low risk category.
SARMs create selective anabolic activity at certain androgen receptors and not others, hence their name. SARMs such as MK-2688 do not have androgenic activity in non-skeletal tissues.
Ostarine SARM:
-Lean mass gains (doses as low as 5mg to cause muscle growth)
-Accelerated fat loss (much moreso than S4 and at doses as low as 5mg ED)
-Joint soothing/healing effects
-Half life is 24 hours (one dose per day optimal)
-Can go up to 50mg ED with no known side effects ( IMO anything beyond 30 is a waste)
Ostarine (CAS# 1235370-13-4) is a research chemical developed by GTx Inc. It is undergoing Phase III (human) research trials in the USA. Ostarine belongs to a class of chemicals known as SARMs or selective androgen receptor modulators. SARMs create selective anabolic activity at certain androgen receptors and not others, hence their name. Compared to testosterone, the sex hormone, the advantage of SARMs such as Ostarine is that they do not have androgenic activity in non-skeletal-muscle tissues.
Testosterone and other androgenic anabolic steroids (AAS) are very effective at preventing muscle-wasting as well as increasing appetite and physical strength in humans and animal test subjects. However, AAS have a specific set of side-effects related to their non-specific androgen receptor activity that makes them contraindicated in many cases where they would otherwise be useful. Additionally, testosterone is subject to enzymatic conversion to a number of other bioactive hormones such as estrogen via the aromatase enzyme and DHT via the 5-alpha-reductase enzyme. While additional drugs may be prescribed to lower aromatase and 5-AR, or to minimize the side effects of AAS in some other fashion, testosterone is primarily only indicated for male hormone replacement therapy due to the fact that it is a problematic and complicated compound to use for its androgenic properties and the side-effects can vary greatly from individual to individual.
Ostarine exerts its anabolic effects on skeletal muscle tissue almost exclusively, and therefore represents a new potential treatment option for a wide spectrum of conditions from age-related muscular atrophy (sarcopenia), AIDS or cancer-related wasting/cachexia, and even an agent to minimize atrophy during recovery periods from serious surgery or similar situations. It is effective in not only maintaining lean body mass (LBM) but actually increases it.
Currently used androgens for male hormone replacement therapy are typically injectable or skin delivery formulations of testosterone or testosterone esters. Injectable forms of testosterone esters (such as testosterone enanthate, propionate, or cypionate) produce undesirable fluctuations in testosterone blood levels, with overly high levels shortly after injection and overly low afterward. Skin patches do provide a better blood level profile of testosterone, but skin irritation and daily application still limit their usefulness. Oral androgens are not currently used due to concerns about liver toxicity.
SARMs provide the opportunity to design molecules that can be delivered orally, but that selectively target the androgen receptors in different tissues differently. The goal of research in this area is to allow a customized response: Tissues that are the target of the therapy will respond as they would to testosterone; other tissues where undesirable side-effects are produced will not.
None of the SARMs yet developed are truly selective for anabolic effects in muscle or bone tissues without producing any androgenic effects in tissues such as the prostate gland, however several non-steroidal androgens show a ratio of anabolic to androgenic effects of greater than 3:1 and up to as much as 10:1, compared to testosterone, which has a ratio of 1:1.[2][3][4]
This suggests that, while SARMs are likely to show some virilizing effects when used at high doses (e.g., use by bodybuilders), at lower therapeutic doses they may well be effectively selective for anabolic effects, which will be important if SARMs are to have clinical application in the treatment of osteoporosis in women. One substantial advantage of even the first-generation SARMs developed to date is that they are all orally active without causing liver damage, whereas most anabolic steroids are not active orally and must be injected, and those anabolic steroids that are orally active tend to cause dose-dependent liver damage, which can become life-threatening with excessive use. Research is continuing into more potent and selective SARMs, as well as optimising characteristics such as oral bioavailability and increased half-life in vivo, and seeing as the first tissue-selective SARMs were only demonstrated in 2003, the compounds tested so far represent only the first generation of SARMs and future development may produce more selective agents compared to those available at present
-Making the best use of it-
if you look are big time body builders they all run long term cycles. It essential for big time growth, growth is slow and the only way to go about it is the slow n steady approach. With all the PH/oral AAS users here I think a bridge between a sarm/ph/sarm is the best approach.
I am partial to SS because of quality/purity reasons but other companies are ok too. I just want the best, and honest, i think they are more potent/anabolic also.
EX.
osta 1-4 @ 20mg
helladrol 4-10 @ 75mg
osta 10-16 @ 30mg (while in pct)
osta @ 15mg / S4 @ 50mg (pulse s4 to avoid vision sides) 1-6
beastdrol/diesel V2 6-10
osta @ 30mg 10-14 (while in pct)
